Megna Matteo, Napolitano Maddalena, Patruno Cataldo, Villani Alessia, Balato Anna, Monfrecola Giuseppe, Ayala Fabio, Balato Nicola
Department of Dermatology, University of Naples Federico II, Naples, Italy.
Dermatol Ther (Heidelb). 2017 Mar;7(1):1-23. doi: 10.1007/s13555-016-0170-1. Epub 2016 Dec 26.
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Due to its chronic nature and frequently occurring relapses, AD has a substantial effect on patients' quality of life, often requiring long-term systemic treatment, especially in adult patients, who are more frequently refractory to adequate topical treatment with mid- to high-potent corticosteroids and/or calcineurin inhibitors. Therefore, treatment with systemic therapies is often needed to take control of the disease, prevent exacerbations and improve quality of life. However, data regarding systemic treatment effectiveness and long-term safety in adult patients with AD are insufficient. Indeed, standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries. This review focuses on the use of systemic treatments in adult AD patients analyzing published literature.
特应性皮炎（AD）是一种常见的慢性炎症性皮肤病，主要影响儿童。然而，它可在成年期持续存在和/或在老年时发病。由于其慢性性质和频繁复发，AD对患者的生活质量有重大影响，通常需要长期的全身治疗，尤其是成年患者，他们对中强效皮质类固醇和/或钙调神经磷酸酶抑制剂的充分局部治疗更常出现耐药。因此，往往需要采用全身治疗来控制疾病、预防病情加重并改善生活质量。然而，关于成年AD患者全身治疗有效性和长期安全性的数据不足。事实上，缺乏标准化的国际指南，不同国家的治疗方法差异很大。本综述重点分析已发表文献中成年AD患者全身治疗的应用情况。
